Rituximab associated late-onset neutropenia—a rheumatology case series and review of the literature

Clinical Rheumatology

Volumn 35, Issue 10, 2016, Pages 2457-2462

  Monaco, William E ^a   Jones, Jonathan D ^a   Rigby, William F C ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Late onset neutropenia; Rheumatic diseases; Rheumatoid arthritis (RA); Rheumatology; Rituximab

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; RITUXIMAB; ANTIRHEUMATIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; BACTEREMIA; BONE MARROW BIOPSY; CELL MATURATION; CLINICAL ARTICLE; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; FOLIC ACID BLOOD LEVEL; GRANULOPOIESIS; HUMAN; INCIDENCE; LATE ONSET DISORDER; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROMYELOCYTE; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; SEPSIS; TERTIARY CARE CENTER; VITAMIN BLOOD LEVEL; WEGENER GRANULOMATOSIS; CASE REPORT; CHEMICALLY INDUCED; RETROSPECTIVE STUDY; RHEUMATIC DISEASES;

ADULT; AGED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; RITUXIMAB;

EID: 84974839148     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3313-y     Document Type: Article

References (20)

1. Pescovitz MD (2006) Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 6:859–66
2. Smolen JS, Aletaha D, Koeller M et al (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370(9602):1861–74
3. Smolen JS, Landewé R, Breedveld FC et al (2010) EULAR recommendations for management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–75
4. Cohen SB, Emery P, Greenwalk MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793–806
5. Becerra E, Cambridge G, de la Torra I, Leandro MJ (2012) Long-term safety of rituximab in patients with rheumatoid arthritis. Int J Clin Rheum 7(4):383–90
6. deLemos LL, Costa JO, Machado MA et al (2014) Rituximab for rheumatoid arthritis: a systematic review. Rev Bras Rheumatol 54(3):220–30
7. van Vollenhoven RF, Emery P, Bingham CO et al (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials (2010). J Rheumatol 37(3):558–67
8. Safa G, Darrieux L (2013) Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med 173(10):924–6
9. Fukuno K, Tsurumi H, Ando N et al (2006) Late-onset neutropenia in patients treated with rituximab for non-Hodgkin’s lymphoma. Int J Hematol 84:242–7
10. Cairoli R, Grillo G, Tedeschi A et al (2004) High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 89:361–3
11. Nitta E, Izutsu K, Sato T et al (2007) A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 18:364–9
12. Abdulkader R, Dharmapalaiah C, Rose G et al (2014) Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol 41(5):858–61
13. Besada E, Koldingsnes W, Nossent J (2012) Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. Q J Med 105:545–50
14. Breuer GS, Ehrenfeld M, Rosner I et al (2014) Late-onset neutropenia following rituximab treatment for rheumatologic conditions. Clin Rheumatol. doi:10.1007/s10067-014-2562-x
15. Tesfa D, Ajeganova S, Hägglund H et al (2011) Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 63(8):2209–14
16. Salmon JH, Cacoub P, Combe B et al (2015) Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. doi:10.1136/rmdopen-2014-000034
17. Tesfa D, Palmblad J (2011) Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 4(6):619–25
18. Greer JP, Foerster J, Rodgers GM et al (2009) Wintrobe’s clinical hematology, 12th edn. Lippincott Williams & Wilkins, Philadelphia, pp 7–20
19. Bredemeier M, de Oliveira FK, Rocha CM (2014) Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 66(2):228–35
20. Grant C, Wilson WH, Dunleavy K (2011) Neutropenia associated with rituximab therapy. Curr Opin Hematol 18:49–54